Maxigen Biotech Inc (1783) - Net Assets
Based on the latest financial reports, Maxigen Biotech Inc (1783) has net assets worth NT$1.47 Billion TWD (≈ $46.43 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.71 Billion ≈ $53.80 Million USD) and total liabilities (NT$234.00 Million ≈ $7.37 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Maxigen Biotech Inc (1783) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.47 Billion |
| % of Total Assets | 86.3% |
| Annual Growth Rate | 10.37% |
| 5-Year Change | 59.86% |
| 10-Year Change | 65.71% |
| Growth Volatility | 33.02 |
Maxigen Biotech Inc - Net Assets Trend (2009–2024)
This chart illustrates how Maxigen Biotech Inc's net assets have evolved over time, based on quarterly financial data. Also explore how large is Maxigen Biotech Inc's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Maxigen Biotech Inc (2009–2024)
The table below shows the annual net assets of Maxigen Biotech Inc from 2009 to 2024. For live valuation and market cap data, see Maxigen Biotech Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.38 Billion ≈ $43.32 Million |
+1.03% |
| 2023-12-31 | NT$1.36 Billion ≈ $42.88 Million |
+5.05% |
| 2022-12-31 | NT$1.30 Billion ≈ $40.82 Million |
+13.48% |
| 2021-12-31 | NT$1.14 Billion ≈ $35.97 Million |
+32.72% |
| 2020-12-31 | NT$860.23 Million ≈ $27.10 Million |
+1.05% |
| 2019-12-31 | NT$851.32 Million ≈ $26.82 Million |
+0.99% |
| 2018-12-31 | NT$842.98 Million ≈ $26.56 Million |
+5.87% |
| 2017-12-31 | NT$796.25 Million ≈ $25.09 Million |
+1.90% |
| 2016-12-31 | NT$781.38 Million ≈ $24.62 Million |
-5.84% |
| 2015-12-31 | NT$829.86 Million ≈ $26.14 Million |
-5.38% |
| 2014-12-31 | NT$877.01 Million ≈ $27.63 Million |
-1.28% |
| 2013-12-31 | NT$888.39 Million ≈ $27.99 Million |
+130.36% |
| 2012-12-31 | NT$385.66 Million ≈ $12.15 Million |
+4.44% |
| 2011-12-31 | NT$369.25 Million ≈ $11.63 Million |
-6.61% |
| 2010-12-31 | NT$395.39 Million ≈ $12.46 Million |
+26.31% |
| 2009-12-31 | NT$313.03 Million ≈ $9.86 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Maxigen Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 40019000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$216.46 Million | 15.74% |
| Common Stock | NT$891.63 Million | 64.84% |
| Other Components | NT$267.03 Million | 19.42% |
| Total Equity | NT$1.38 Billion | 100.00% |
Maxigen Biotech Inc Competitors by Market Cap
The table below lists competitors of Maxigen Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eolus Vind AB (publ)
ST:EOLU-B
|
$109.91 Million |
|
Amorepacific Group
KO:002795
|
$109.93 Million |
|
Lassila &Tikanoja Oyj
HE:LAT1V
|
$109.99 Million |
|
Southern Acids (M) Bhd
KLSE:5134
|
$110.01 Million |
|
Bajaj Healthcare Limited
NSE:BAJAJHCARE
|
$109.90 Million |
|
BIOCELTIX S.A. ZY -10
F:XI3
|
$109.87 Million |
|
Panasonic Manufacture Malaysia
KLSE:3719
|
$109.81 Million |
|
Sat Industries Limited
NSE:SATINDLTD
|
$109.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Maxigen Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,361,103,000 to 1,375,127,000, a change of 14,024,000 (1.0%).
- Net income of 190,167,000 contributed positively to equity growth.
- Dividend payments of 88,957,000 reduced retained earnings.
- New share issuances of 28,686,000 increased equity.
- Other comprehensive income decreased equity by 272,315,000.
- Other factors increased equity by 156,443,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$190.17 Million | +13.83% |
| Dividends Paid | NT$88.96 Million | -6.47% |
| Share Issuances | NT$28.69 Million | +2.09% |
| Other Comprehensive Income | NT$-272.31 Million | -19.8% |
| Other Changes | NT$156.44 Million | +11.38% |
| Total Change | NT$- | 1.03% |
Book Value vs Market Value Analysis
This analysis compares Maxigen Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.54x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.62x to 2.54x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$6.92 | NT$38.90 | x |
| 2010-12-31 | NT$7.25 | NT$38.90 | x |
| 2011-12-31 | NT$6.69 | NT$38.90 | x |
| 2012-12-31 | NT$6.77 | NT$38.90 | x |
| 2013-12-31 | NT$13.26 | NT$38.90 | x |
| 2014-12-31 | NT$11.37 | NT$38.90 | x |
| 2015-12-31 | NT$10.67 | NT$38.90 | x |
| 2016-12-31 | NT$10.18 | NT$38.90 | x |
| 2017-12-31 | NT$10.41 | NT$38.90 | x |
| 2018-12-31 | NT$9.88 | NT$38.90 | x |
| 2019-12-31 | NT$9.69 | NT$38.90 | x |
| 2020-12-31 | NT$10.67 | NT$38.90 | x |
| 2021-12-31 | NT$13.58 | NT$38.90 | x |
| 2022-12-31 | NT$14.49 | NT$38.90 | x |
| 2023-12-31 | NT$15.22 | NT$38.90 | x |
| 2024-12-31 | NT$15.33 | NT$38.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Maxigen Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.83%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 27.94%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.15x
- Recent ROE (13.83%) is above the historical average (2.97%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 4.03% | 6.99% | 0.53x | 1.10x | NT$-18.68 Million |
| 2010 | -4.05% | -9.28% | 0.40x | 1.09x | NT$-55.54 Million |
| 2011 | -9.77% | -20.17% | 0.37x | 1.32x | NT$-73.00 Million |
| 2012 | 0.72% | 1.25% | 0.44x | 1.31x | NT$-35.80 Million |
| 2013 | 0.29% | 1.11% | 0.23x | 1.14x | NT$-86.26 Million |
| 2014 | -2.17% | -7.75% | 0.24x | 1.16x | NT$-106.74 Million |
| 2015 | -7.59% | -24.08% | 0.22x | 1.41x | NT$-145.94 Million |
| 2016 | -1.57% | -3.64% | 0.31x | 1.40x | NT$-90.38 Million |
| 2017 | 1.98% | 3.69% | 0.39x | 1.39x | NT$-63.84 Million |
| 2018 | 6.77% | 13.34% | 0.38x | 1.35x | NT$-27.24 Million |
| 2019 | 7.06% | 13.29% | 0.38x | 1.39x | NT$-25.02 Million |
| 2020 | 7.36% | 13.83% | 0.48x | 1.11x | NT$-22.71 Million |
| 2021 | 7.68% | 17.12% | 0.40x | 1.11x | NT$-26.50 Million |
| 2022 | 10.76% | 23.06% | 0.42x | 1.12x | NT$9.84 Million |
| 2023 | 12.18% | 26.66% | 0.42x | 1.10x | NT$29.72 Million |
| 2024 | 13.83% | 27.94% | 0.43x | 1.15x | NT$52.65 Million |
Industry Comparison
This section compares Maxigen Biotech Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,415,119,778
- Average return on equity (ROE) among peers: 12.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Maxigen Biotech Inc (1783) | NT$1.47 Billion | 4.03% | 0.16x | $109.91 Million |
| St.Shine Optical Co Ltd (1565) | $2.47 Billion | 35.35% | 0.46x | $164.40 Million |
| SciVision Biotech Inc (1786) | $1.02 Billion | -2.16% | 0.07x | $135.56 Million |
| Bioteque (4107) | $1.17 Billion | 26.36% | 0.41x | $252.17 Million |
| Chi Sheng Chemical (4111) | $1.05 Billion | 4.04% | 0.44x | $55.51 Million |
| BenQ Medical Technology (4116) | $1.11 Billion | 6.82% | 0.53x | $56.09 Million |
| Pacific Hospital Supply Co Ltd (4126) | $2.83 Billion | 14.85% | 0.33x | $181.84 Million |
| Bionime Corp (4737) | $1.35 Billion | 4.03% | 2.46x | $151.21 Million |
| Vizionfocus Inc. (4771) | $1.29 Billion | 11.32% | 0.69x | $347.59 Million |
| Formosa Optical Technology Co Ltd (5312) | $447.89 Million | 9.57% | 0.73x | $183.92 Million |
About Maxigen Biotech Inc
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone materials; beauty care products; and medical devices for ophthalmology, otola… Read more